Sign up and fund a new Wall St account and get a full U.S. share.Sign up and fund a new Wall St account and get a full share randomly chosen between GoPro, Dropbox or Nike.T&Cs apply
Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of ITK inhibition as a new approach to immunotherapy for a range of cancer and immune diseases. Its lead product candidate is soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. ITK, an enzyme that functions in T cell signaling and differentiation, is expressed predominantly in T cells. Its second product candidate, ciforadenant, is an oral, small molecule antagonist of the A2A receptor for adenosine designed to disable a tumor’s ability to subvert attack by the immune system by blocking the binding of immunosuppressive adenosine in the tumor microenvironment to the A2A receptor. The Company’s third product candidate is mupadolimab, a humanized monoclonal antibody that is designed to react with a specific site on CD73.
Find out what a historical investment in Corvus Pharmaceuticals Inc would be worth today using our CRVS stock calculator.
Buying CRVS shares in Australia can be done through an online investing platform, such as Stake. Follow the simple steps below to start investing in Corvus Pharmaceuticals Inc in minutes.
Sign up with some I.D. and zero paperwork
Add funds to your account
Make your first investment in CRVS
What is the ticker symbol of Corvus Pharmaceuticals Inc?
The ticker symbol for Corvus Pharmaceuticals Inc is CRVS.
How much is one share of CRVS?
One share of CRVS is valued at $10.01 as of 20 November 2026.
What is the market capitalisation of Corvus Pharmaceuticals Inc CRVS?
As of 20 November 2026 Corvus Pharmaceuticals Inc has a market cap of $859.56M.
What is the 52-week high for Corvus Pharmaceuticals Inc stock?
The Corvus Pharmaceuticals Inc 52-week high stock price is $26.95.
What is the 52-week low for Corvus Pharmaceuticals Inc stock?
The Corvus Pharmaceuticals Inc 52-week low stock price is $6.39.
Can I buy CRVS shares through Stake, an investing platform like CommSec, Selfwealth or Superhero?
Yes, the Stake investing platform allows you to buy CRVS shares and over 13,000 more stocks and ETFs across the ASX and Wall St.
This is not financial product advice nor a recommendation to invest in the securities listed. Past performance is not a reliable indicator of future performance. As always, do your own research and consider seeking financial, legal and taxation advice before investing. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.
Invest in CRVS on Stake
Buy CRVS from US$3 brokerage
Invest in 11,000+ U.S. stocks and ETFs
Own a slice of CRVS from only US$10 with fractional shares